Fatty Acid Biosynthesis Inhibitors─Fabimycin and Triclosan─Trigger Distinct Resistance Mutations in FabI and Potently Kill Gram-Negative Pathogens
- 24 August 2026
- journal article
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (9) , 3159-3168
Abstract
In an effort to develop efficacious antibacterials that engage targets for which there is no preexisting resistance, inhibition of the enoyl-acyl carrier protein reductase FabI has shown promise, with triclosan and fabimycin as representative members of the two major drug classes that show activity against important bacterial pathogens. Here, we use a morbidostat and whole-genome sequencing approach to comprehensively evaluate the resistance profiles that arise in pathogenic bacteria in response to these FabI inhibitors. When assessed against E. coli, fabimycin and triclosan were found to induce primarily nonoverlapping resistance profiles, leading to minimal cross-resistance between the two compounds. Furthermore, in vivo evaluation of the prominent resistant mutants indicates poor fitness, with the fittest mutant still susceptible to fabimycin. Collectively, these results suggest the combination use of two antibiotics that engage different positions on the same target as a means to kill pathogenic bacteria and limit resistance.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01AI167977)
- National Institute of Allergy and Infectious Diseases (R01AI176523)
- University of Illinois at Urbana-Champaign
This publication has 36 references indexed in Scilit:
- The bactericidal FabI inhibitor Debio 1453 clears antibiotic-resistant Neisseria gonorrhoeae infection in vivoNature Communications, 2025
- Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050The Lancet, 2024
- An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate with In Vivo Efficacy against Drug-Resistant Gram-Negative InfectionsACS Central Science, 2022
- FabI (enoyl acyl carrier protein reductase) - A potential broad spectrum therapeutic target and its inhibitorsEuropean Journal of Medicinal Chemistry, 2020
- Mutual potentiation drives synergy between trimethoprim and sulfamethoxazoleNature Communications, 2018
- Building a morbidostat: an automated continuous-culture device for studying bacterial drug resistance under dynamically sustained drug inhibitionNature Protocols, 2013
- From Triclosan toward the Clinic: Discovery of Nonbiocidal, Potent FabI Inhibitors for the Treatment of Resistant BacteriaJournal of Medicinal Chemistry, 2012
- A framework for variation discovery and genotyping using next-generation DNA sequencing dataNature Genetics, 2011
- Multi-targeting by monotherapeutic antibacterialsNature Reviews Drug Discovery, 2007
- Triclosan targets lipid synthesisNature, 1998